MD Anderson Cancer Center
1515 Holcombe Boulevard
Houston
Texas
77030
United States
Tel: 1-877-731-7527
Website: http://www.mdanderson.org/
308 articles with MD Anderson Cancer Center
-
Genome engineering company Replay and the MD Anderson Cancer Center have joined forces to launch Syena, an oncology product company.
-
MD Anderson and Federation Bio Announce Collaboration to Develop Novel Microbiome Treatment for Patients with Immunotherapy-Resistant Cancers
2/1/2023
The University of Texas MD Anderson Cancer Center and Federation Bio today announced a strategic collaboration to design and manufacture a complex, synthetic microbial consortium with the goal of expanding the number of cancer patients who respond to immunotherapy.
-
TC BioPharm and MD Anderson signed a three-year collaboration to better understand the role of gamma delta T cells in cancer treatment.
-
TC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology
1/17/2023
TC Biopharm today announces a strategic collaboration with The University of Texas MD Anderson Cancer Center to expand the knowledge base of how gamma-delta T cells work in oncology settings.
-
In a recently published study, MD Anderson researchers achieved curative responses in pancreatic cancer models by targeting checkpoints in T cells and myeloid suppressor cells.
-
Concord Medical Announces the Successful Holding of the Second Annual Academic Meeting with the world well-known MD Anderson
11/16/2022
Concord Medical Services Holdings Limited announced the successful holding of the Second Annual Academic Meeting jointly by Shanghai Concord Cancer Center and The University of Texas MD Anderson Cancer Center on November 11 and November 12, 2022.
-
Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments
11/14/2022
Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD Anderson in order to advance novel small-molecule oncology therapies.
-
Angle PLC Announces Multiple Downstream Analysis Techniques for CTCs
11/2/2022
ANGLE plc is delighted to announce the publication of results from a multi-centre clinical study undertaken with The University of Texas MD Anderson Cancer Center, TX, Wilmot Cancer Institute, University of Rochester, NY, Robert H Lurie Comprehensive Cancer Center, Northwestern University, IL, and Norris Comprehensive Cancer Center, University of Southern California, CA, US.
-
Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies
11/1/2022
Eterna Therapeutics Inc. today announced it has entered into a sponsored research agreement with Michael Andreeff, M.D., Ph.D., Professor of Leukemia at The University of Texas MD Anderson Cancer Center (“MD Anderson”).
-
MD Anderson and ARTIDIS Announce Strategic Alliance to Advance Nanomechanical Technology Platform for Optimizing Cancer Treatment
10/3/2022
ARTIDIS AG and The University of Texas MD Anderson Cancer Center announced a strategic alliance to investigate ARTIDIS technology as a novel treatment-optimization tool for patients with solid tumors in several distinct indications.
-
Neuronal Inflammation was found in two U.S. monkeypox patients, researchers short-list four drugs for potential study in autism and a new test can predict immunotherapy outcomes.
-
MD Anderson and Radiopharm Theranostics Launch Joint Venture to Develop Novel Radiopharmaceuticals
9/14/2022
The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics Limited announced the launch of Radiopharm Ventures, LLC, a joint venture company created to develop novel radiopharmaceutical therapeutic products for cancer.
-
MD Anderson and Empyrean Announce Agreement to Develop Novel Radiation Therapy Technologies
8/10/2022
The University of Texas MD Anderson Cancer Center and Empyrean Medical Systems, Inc. announced an exclusive license and joint development agreement to advance novel technologies and products in the fields of radiation oncology and cancer therapeutics.
-
AbbVie and Sosei add neurological targets in new deal, TransCode and MD Anderson partner on RNA cancer therapies and Xenetic and VolitionRx unite to develop NETs-targeted therapies against cancer.
-
FDA Weekly Review looks at the FDA's actions related to drug approvals, IND approvals, designations and more. Here’s a look at what happened this week.
-
Researchers at MD Anderson Cancer Center have uncovered a new method in which some solid tumor cells are evading detection: the formation of their own type of collagen.
-
MD Anderson and Obsidian Therapeutics announce FDA Clearance of IND application for novel TIL therapy OBX-115
7/21/2022
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for an MD Anderson-sponsored Phase I clinical study of OBX-115, Obsidian's lead engineered tumor infiltrating lymphocyte (TIL) therapy candidate.
-
INVECTYS, MD ANDERSON AND CTMC ANNOUNCE STRATEGIC COLLABORATION FOR CAR T CELL THERAPY DEVELOPMENT
6/16/2022
Invectys, Inc. (Invectys), The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), a joint venture between MD Anderson and National Resilience, Inc., today announced a strategic collaboration to jointly develop a reliable, compliant and scalable process for human leukocyte antigen (HLA)-G targeted chimeric antigen receptor (CAR) T cell therapy for solid tumors.
-
Primary seven-year data from Janssen's (Johnson & Johnson) Phase III trial of Imbruvica (ibrutinib) in lymphoma demonstrated positive survival outcomes.
-
Top research stories, including gene regulation and longevity, a head-to-head comparison of COVID-19 vaccines, a newly discovered type of brain cell and more.